Skip to main content

Hemab Therapeutics Holdings, Inc.

corporate_fare Company Profile

Hemab Therapeutics Holdings, Inc.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed COAG - Latest Insights

COAG
May 06, 2026, 7:16 PM EDT
Filing Type: 4
Importance Score:
9
RA Capital, a 10% Owner and Director, Makes Substantial $172M Post-IPO Investment in Hemab Therapeutics
Sentiment: Positive
View Wiseek Article
COAG
May 04, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Hemab Therapeutics Completes Upsized IPO with Full Over-Allotment, Securing $346.7M in Gross Proceeds
Sentiment: Positive
View Wiseek Article
COAG
May 01, 2026, 4:14 PM EDT
Filing Type: 424B4
Importance Score:
9
Hemab Therapeutics Finalizes $301.5M Upsized Initial Public Offering to Advance Clinical Pipeline
Sentiment: Positive
View Wiseek Article
COAG
Apr 30, 2026, 6:55 PM EDT
Source: GlobeNewswire
Importance Score:
9
Hemab Therapeutics Prices Upsized IPO at $18/Share, Raising $301.5M Ahead of Nasdaq Debut
Sentiment: Positive
View Wiseek Article